4 analysts have expressed a variety of opinions on Augmedix (NASDAQ:AUGX) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
1
1
0
0
Last 30D
0
1
0
0
0
1M Ago
2
0
1
0
0
2M Ago
0
0
0
0
0
3M Ago
0
0
0
0
0
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $5.0, a high estimate of $5.50, and a low estimate of $4.50. A decline of 14.24% from the prior average price target is evident in the current average.
Decoding Analyst Ratings: A Detailed Look
A clear picture of Augmedix's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Elizabeth Anderson
Evercore ISI Group
Raises
Outperform
$5.00
$4.50
Neil Chatterji
B. Riley Securities
Announces
Buy
$5.50
-
Elizabeth Anderson
Evercore ISI Group
Lowers
In-Line
$4.50
$6.50
Allen Klee
Maxim Group
Lowers
Buy
$5.00
$6.50
Key Insights:
Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Augmedix. This insight gives a snapshot of analysts' perspectives on the current state of the company.
Rating: Unveiling insights, analysts ...Full story available on Benzinga.com
Related tickers: AUGX.
Read Full Article